Key result
Tiotropium shows no effect on ECG or Holter parameters compared to placebo.
Why the study?
Does tiotropium cause adverse electrocardiographic changes or arrhythmias in patients with COPD?
Population
Patients with chronic obstructive pulmonary disease (COPD) enrolled in multiple clinical trials (n=2,418)
Comparison
Tiotropium administered for 4 weeks to 12 months vs Placebo
Design
Meta-analysis, placebo-controlled
Follow-up
up to 12 months
Authors
Loading...
Supports tiotropium cardiac safety in COPD without routine ECG concerns; confirms no electrophysiologic effects in pooled randomized data.
Does tiotropium cause adverse electrocardiographic changes or arrhythmias in patients with COPD?
Tiotropium use in COPD patients is not associated with adverse electrocardiographic changes or an increased risk of arrhythmias.
Morganroth et al. (2004) studied chronic obstructive pulmonary disease (n=2,418). Tiotropium vs. Placebo was evaluated on Electrocardiogram or Holter outcome parameters (heart rate, atrio-ventricular conduction, ventricular or supraventricular arrhythmias). Tiotropium (up to 36 mcg daily) was not associated with any significant differences in electrocardiogram or Holter outcome parameters compared to placebo across 2,418 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: